Evidence map›Paper›PMID 28743748›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Design and synthesis of theranostic antibiotic nanodrugs that display enhanced antibacterial activity and luminescence.

Sheng Xie, Sesha Manuguri, Giampiero Proietti, Joakim Romson, Ying Fu, A Ken Inge, Bin Wu, Yang Zhang, Daniel Häll, Olof Ramström and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 101 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. A self-assembled and HTheranostics · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. The evolution of clinical guidelines for antimicrobial photodynamic therapy of skin.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022
    Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Sheng XieDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Sesha ManuguriDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Giampiero ProiettiDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Joakim RomsonDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Ying FuDepartment of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, SE-171 21, Solna, Sweden.
A Ken IngeDepartment of Materials and Environmental Chemistry, Stockholm University, S-10691, Stockholm, Sweden.
Bin WuDepartment of Chemistry, University of Massachusetts, Lowell, MA 01854.
Yang ZhangDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Daniel HällDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden.
Olof RamströmDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden; ramstrom@kth.se mingdi@kth.se.
Mingdi YanDepartment of Chemistry, KTH Royal Institute of Technology, Teknikringen 30, S-10044, Stockholm, Sweden; ramstrom@kth.se mingdi@kth.se.
KTH Royal Institute of Technology · SEUniversity of Massachusetts Lowell · USStockholm University · SE

Funding

Photogenerated Carbohydrate MicroarraysR01GM080295 · NIGMS · UNIVERSITY OF MASSACHUSETTS LOWELL · PI YAN, MINGDI · 2008 to 2012
$2.0M
Maltoheptaose based nanotherapeutics for multidrug resistant bacterial infectionR21AI109896 · NIAID · UNIVERSITY OF MASSACHUSETTS LOWELL · PI YAN, MINGDI · 2014 to 2015
$444k
NIAID NIH HHS R21 AI109896NIGMS NIH HHS R01 GM080295
6 · The paper itself

Abstract

We report the modular formulation of ciprofloxacin-based pure theranostic nanodrugs that display enhanced antibacterial activities, as well as aggregation-induced emission (AIE) enhancement that was successfully used to image bacteria. The drug derivatives, consisting of ciprofloxacin, a perfluoroaryl ring, and a phenyl ring linked by an amidine bond, were efficiently synthesized by a straightforward protocol from a perfluoroaryl azide, ciprofloxacin, and an aldehyde in acetone at room temperature. These compounds are propeller-shaped, and upon precipitation into water, readily assembled into stable nanoaggregates that transformed ciprofloxacin derivatives into AIE-active luminogens. The nanoaggregates displayed increased luminescence and were successfully used to image bacteria. In addition, these nanodrugs showed enhanced antibacterial activities, lowering the minimum inhibitory concentration (MIC) by more than one order of magnitude against both sensitive and resistant

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsBacteriaCiprofloxacinDrug DesignDrug Resistance, BacterialFluoroquinolonesLuminescenceMicrobial Sensitivity TestsTheranostic NanomedicineAnti-Bacterial AgentsAnti-Infective AgentsCiprofloxacinFluoroquinolonesaggregation-induced emissionfluoroquinolonesnanodrugs

Identifiers

PMID28743748
PMCPMC5559051
OpenAlexW2737198255

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.